When is a technology sublicensed from an Alfred E. Mann Institute?
Medical devices under development at an AMI are generally developed through product qualification, or, if indicated, through clinical trials. Very rarely sublicensing of medical devices may be pursued at an earlier stage based on specific market dynamics. Although the AMIs are broadly focused on the development of biomedical technologies, selected pharmaceutical or biologic projects may also be considered for development; if one of these latter areas is selected for development within an AMI, due to the high cost and lengthy time requirements for development and clinical trials, it is anticipated that bio/pharmaceuticals will not generally continue beyond completion of Phase 2A.. The AMI Executive Director, in conjunction with the Board of Directors, will determine the point at which commercialization via sublicensing is appropriate.
